Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| SUMMER INFAN | SUMR | 7.83% |
| FEDERAL MOGU | FDML | 6.25% |
| NATUS MEDICA | BABY | 5.62% |
| RADIANT LOGI | RLGT | 5.31% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
The Financial Industry Regulatory Authority (FINRA) has decided to appeal to its appellate body – the National Adjudicatory Council – against The Charles Schwab Corporation ( SCHW - Analyst Report ) . The decision comes after a FINRA hearing panel approved Schwab’s demand to ban class-action lawsuits.
The hearing panel had approved the ban citing it as consistent with the Federal law and the latest Supreme Court analysis of the Federal Arbitration Act. Also, the panel found that though limiting customer’s class action and arbitration rights is against the FINRA rules, it is also in conflict with Federal Arbitration Act, and hence cannot be enforced.
Schwab succeeded in getting the approval for the ban, but on the other hand the hearing panel disallowed its demand to block arbitrators from uniting individual arbitration claims into group hearings. Moreover, the panel penalized Schwab $500,000 for including the group ban in its client contracts. This was a partial win for FINRA.
It all started last year with Schwab revising its customer agreements to incorporate a class-action waiver condition requiring that all disagreements between the brokerage firm and its clientele be arbitrated. This was in contradiction of the FINRA guidelines.
The ruling will profoundly influence the entire industry and is a blow to the FINRA. Schwab is likely to seek dismissal of pending class-action lawsuits. Other brokerage firms, including TD Ameritrade Holding Corporation ( AMTD - Analyst Report ) , E*TRADE Financial Corporation ( ETFC - Analyst Report ) and Interactive Brokers Group, Inc. ( IBKR - Analyst Report ) , may also follow similar suit.
If other brokerage firms start following the suit, it would raise severe investor protection concerns. It is likely to prevent consumers from following class-action litigation due to inability of FINRA’s dispute-resolution forum to handle these types of cases. Moreover, it would strip customers of their right to pursue smaller claims.
We believe that FINRA’s action to appeal against the ban of class-action lawsuit is well justified and is totally in the interest of the consumers.
Schwab carries a Zacks Rank #2 (Buy).
Read the full reports :
Analyst Report on ETFC
Analyst Report on SCHW
Analyst Report on IBKR
Analyst Report on AMTD